What Reyataz Treats: Main Uses and Benefits

Reyataz is applied as part of an antiretroviral combination regimen to address Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and children.

---

The goal of this therapy is to help achieve and support virologic suppression, which involves reducing the viral load to low or undetectable levels. This medicine is commonly used to help with the management of HIV-1 infection, supporting the patient during phases marked by detectable viremia and advancing immunodeficiency.

Sustained Support and Therapeutic Advantages

This therapy supports the maintenance of the patient’s immune system, specifically CD4+ T-cell counts. This support is generally considered helpful in sustaining the body's natural defenses and may assist with delaying the development of opportunistic infections and other illnesses associated with the condition. The treatment is commonly used across a wide range of individuals, including adults, pediatric patients, and pregnant individuals.

“This medicine is applied to help reduce the viral load and assist in sustaining immune function over the long term.”

Quick Fact: Relief for Chronic Viral Burden
Primary Indication	Human Immunodeficiency Virus type 1 (HIV-1) infection
Main Therapeutic Goal	Achieving and supporting virologic suppression
Core Benefit	Assisting with the maintenance of immune system stability

Eligibility Map: Who can and cannot use Reyataz — Official Regulatory Information

The eligibility for Reyataz (atazanavir) is strictly defined by regulatory documents based on age, organ function, and specific medical history.

Category	Official Regulatory Status
Populations for whom use is allowed	Adults and pediatric patients 3 months of age and older who weigh at least 5 kg (oral powder) or 6 years of age and older (capsules).
Populations for whom use is not recommended	Pediatric patients below 3 months of age; treatment-experienced patients with end-stage renal disease (ESRD) on hemodialysis; and unboosted regimens in patients with prior virologic failure.
Populations for whom use is contraindicated	Patients with a known hypersensitivity to any component of the product, and patients with severe hepatic impairment (liver failure).
Condition-specific restrictions	The ritonavir-boosted regimen is not recommended for use in patients with any degree of hepatic impairment (mild, moderate, or severe). The oral powder formulation contains phenylalanine, restricting its use in patients with phenylketonuria (PKU).
Pregnancy and lactation eligibility	Pregnancy is a conditional use, generally requiring the ritonavir-boosted regimen; use is permitted only if the potential benefit justifies the potential risk. Lactation is not recommended due to the potential risk of postnatal HIV transmission.

---

The official label establishes absolute exclusion for patients with severe liver impairment and confirmed hypersensitivity. Eligibility is also constrained by minimum age and weight thresholds for children, as well as specific restrictions concerning kidney function and treatment history.

Interactions with other medicines and products

Reyataz (Atazanavir) has a detailed interaction profile based on its function as an inhibitor of the CYP3A4 and UGT1A1 metabolic enzymes. This enzymatic inhibition means that co-administration may increase plasma concentrations of many other medicines that are substrates for these pathways. Conversely, medicines that are strong CYP3A4 inducers, such as Rifampin and St. John’s Wort, are formally contraindicated as they significantly decrease Atazanavir exposure, risking therapeutic failure.

---

Administration Requirements and Prohibitions

Interaction Type	Official Regulatory Statement
**Contraindicated Combinations**	Formal prohibition against co-administering with drugs like **Simvastatin**, **Lovastatin**, **Alfuzosin**, and oral **Midazolam** due to potential for serious adverse events.
**Gastric Acidity Dependence**	The medicine **must be taken with food** to enhance bioavailability. Acid-reducing agents (**PPIs, H2RAs, Antacids**) **reduce Atazanavir concentrations** and require mandated timing separation or are restricted.
**Specific Restrictions**	Co-administration with **Tenofovir Disoproxil Fumarate** officially **decreases Atazanavir exposure**. Use in patients with moderate or severe **hepatic impairment** is not recommended with ritonavir boosting.

How Reyataz Works

Reyataz (atazanavir) acts by intervening directly in the core machinery the Human Immunodeficiency Virus (HIV-1) uses to propagate itself. Its mechanism targets the structural enzyme required for viral assembly.

Specific Targeting of HIV-1 Protease

This drug primarily acts as a selective inhibitor within domains involving enzyme-mediated signaling of the virus. Atazanavir binds to the active site of the essential HIV-1 protease enzyme, preventing it from performing its function. This mechanism is relevant in systems where targeted pathway adjustment is required to interfere with the mechanistic sequence required for the production of new virions.

Disruption of Viral Protein Processing

The mechanistic cascade initiated by protease inhibition blocks the cleavage of large Gag and Gag-Pol polyproteins into the smaller, functional proteins required for the virus core. This action modifies early molecular steps that define the outcome of the viral assembly sequence. The result is the formation of structurally immature and non-infectious virions. The interference with viral protein cleavage reduces the output of new, infectious particles, restricting the completion of the viral maturation cascade.

How to Use Reyataz (Atazanavir)

Reyataz (atazanavir) is prescribed for oral administration only and is administered as a single dose once daily. The medicine is available in hard capsule and oral powder formulations.

For most adult patients, the standard regimen involves 300 mg of atazanavir, which must be co-administered with 100 mg of ritonavir or another pharmacokinetic boosting agent. The dose must always be taken with food to ensure proper oral absorption and bioavailability.

The standard treatment duration is long-term, as it functions as an essential part of a comprehensive, multi-drug antiretroviral plan. The administration of capsules requires them to be swallowed whole and not opened. The oral powder, which is typically used for pediatric patients, must be mixed with food or liquid and consumed within one hour of preparation.

Specific dose adjustments are required for certain populations, including pediatric patients, where dosage is calculated based on body weight, and individuals with hepatic impairment. Furthermore, special timing separation is mandated when co-administering with certain acid-reducing medications.

If a scheduled dose is missed, it should be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, the missed dose should be skipped entirely to maintain the designated single-daily schedule.

Reyataz: Overview of Studies

Evidence for use in Treatment-Naïve Adult Patients

Reyataz was studied for use in adult patients who were evaluated in clinical trials as they began combination therapy for HIV-1 infection for the first time. These research examined primarily randomized controlled trials, which compared the use of the agent alongside other antiretroviral medicines to control groups or other standard regimens. The outcomes related to systemic or functional imbalance that were monitored included measuring changes in viral load (the amount of HIV in the blood) and CD4 cell counts (a measure of immune system health) over defined time intervals. The research highlights changes measured during the study period, and studies reported patterns of change in viral load and CD4 counts consistent with viral suppression measurements. Long-term outcomes are not well characterized beyond the observed trial periods.

---

Evidence for use in Treatment-Experienced Adult Patients

Research was also observed in patients who had previously taken other antiretroviral medications. These studies explored the use of the agent, often comparing its study activity against other established drugs in similar scenarios. Studies monitored changes in viral load and CD4 counts. Research describes patterns of viral load changes consistent with viral suppression measurements in observed cohorts, and the patterns of change measured in these more complex scenarios, where patients often have a history of resistance. Evidence quality varies across studies and data for certain groups remain insufficient.

---

What is still uncertain about Reyataz

Several aspects related to the agent and its study context are still emerging. Research is ongoing to better understand the study context of Reyataz in the context of newer combination therapies. Comparative evidence is lacking for many head-to-head comparisons. The findings were mixed regarding the measured changes in patients who have already experienced multiple treatment failures. Studies help show what has been observed so far, but they do not determine whether an individual will respond similarly.

Common questions about Reyataz (FAQ)

---

Q: Can Reyataz make my skin or eyes look yellow?

A: Yellowing of the skin or eyes (jaundice or scleral icterus) is described in official product information as a very common finding. This is generally due to an increase in a substance called bilirubin in the blood. This elevation is usually asymptomatic (meaning it doesn't cause symptoms) and may be reversed if the medicine is stopped.

---

Q: Does Reyataz cause kidney problems?

A: Official regulatory documents indicate that some patients taking Reyataz have reported cases of nephrolithiasis (kidney stones) and Chronic Kidney Disease during post-marketing surveillance. Regulatory documents mention that healthcare providers may monitor kidney function. Consideration of alternative treatments is described in official labeling if progressive renal disease develops.

---

Q: What is the connection between Reyataz and gallstones?

A: Post-marketing surveillance reports have noted the occurrence of cholelithiasis (gallstones) in patients receiving Reyataz. Official prescribing information indicates that consideration of temporary interruption or discontinuation of the medicine may be necessary in such cases.

---

Q: Does Reyataz affect cholesterol levels?

A: Clinical trial data indicate that Reyataz use is associated with increases in several types of cholesterol and triglycerides (fats) in the blood. Official information reports that these increases were generally lower compared to certain other medicines in the same drug class.

---

Q: Can Reyataz interact with birth control pills?

A: Yes, official drug interaction information states that Reyataz can interact with hormonal contraceptives. This medicine may increase the concentration of certain birth control components or, in some cases, decrease the effectiveness of others. The full prescribing information contains specific guidance regarding reliable contraception methods when using this medicine.

---

Q: How long does it typically take for Reyataz to start working?

A: The medicine is quickly absorbed into the body, reaching its highest level in the blood in about 2.5 hours. The time it takes for Reyataz to achieve its full therapeutic effect—measured as a sustained decrease in the amount of HIV virus in the blood—is typically observed over a period of weeks to months in clinical studies.

---

Q: Is Reyataz the same as other HIV medicines?

A: No, Reyataz is classified as an Antiretroviral Agent but belongs specifically to the class of Protease Inhibitors (PIs). This means it works by targeting a specific enzyme, HIV-1 protease, which is different from the way other classes of HIV medicines (like NRTIs or Integrase Inhibitors) work.

---

Q: Do I take Reyataz alone or with other drugs?

A: Regulatory documents state that Reyataz must always be taken as part of a combination regimen with other antiretroviral agents. Co-administration with a pharmacokinetic enhancer, such as ritonavir or cobicistat, is specified in official labeling to optimize the concentration of the drug in the body.

---

Q: Is Reyataz safe for long-term use?

A: The official documentation describes the intended treatment duration as long-term for managing HIV infection. However, the prescribing information details several serious conditions that can occur over time, such as changes in body fat distribution and chronic kidney disease, which are conditions that may warrant ongoing monitoring.

---

Q: Do older adults need a different dose of Reyataz?

A: Official information regarding use in older adults (aged 65 years and older) indicates that there is no specific dose adjustment recommended for this population, provided they have normal liver and kidney function. The dosage is generally considered the same as for younger adults.

---

Q: Is Reyataz still effective if I have been on other HIV drugs before?

A: Yes. Clinical studies indicated patterns of change consistent with viral suppression in patients who have previously been treated with other antiretroviral medicines. The effectiveness observed in these patients is generally dependent on the number and type of pre-existing protease inhibitor resistance mutations in the virus.

---

Q: Why do some people switch from Reyataz to a different medication?

A: Official documents indicate that patients may switch due to common side effects like jaundice (yellowing of the eyes) that can cause cosmetic concerns. Furthermore, the prescribing information notes that treatment discontinuation may be necessary if severe adverse reactions or specific drug interactions occur.

---

Q: Will Reyataz affect my ability to drive or operate machinery?

A: Official drug information suggests that caution is warranted before driving or operating machinery. Common side effects such as dizziness and fatigue (extreme tiredness) have been reported, and these effects may impact a person's alertness and ability to concentrate.

---

Q: Does taking Reyataz mean I have to get frequent blood tests?

A: Yes. Official prescribing information indicates that blood tests are recommended before starting and while continuing treatment with Reyataz. This testing is necessary to monitor for potential side effects, including changes in liver enzyme levels, kidney function, and blood fats such as cholesterol and triglycerides.

---

Q: Can Reyataz be taken if I have a history of diabetes?

A: Official prescribing information states that new-onset or worsening of diabetes mellitus (sugar diabetes) and hyperglycemia (high blood sugar) have been reported with protease inhibitors. Official labeling states that close monitoring is described for patients with a history of these conditions.

---

Q: Is it normal to feel more tired when first starting Reyataz?

A: Yes. Official documentation lists fatigue (a feeling of extreme tiredness or loss of energy) as a common side effect that has been reported by patients taking the medicine.

---

Q: How long does Reyataz stay in your system?

A: Reyataz has an elimination half-life of approximately 6.5 hours in the blood. This half-life is the time it takes for half of the dose to be eliminated. The drug reaches steady-state, which is a consistent concentration in the blood, after approximately 4 to 8 days of continuous daily dosing.

---

Q: Can Reyataz be taken if I am lactose intolerant?

A: The capsule formulation of Reyataz contains lactose monohydrate as an inactive ingredient. Official labeling indicates that the capsule form is generally not recommended for patients with rare hereditary problems such as lactose intolerance.

Official Storage and Disposal Requirements

Item	Requirement
Storage Temperature	Capsules: Controlled room temperature, 20 C to 25 C (68 F to 77 F), protected from excessive heat and moisture. Oral Powder: 20 C to 30 C (68 F to 86 F).
Container Rules	Keep capsules in the original container, tightly closed. Keep oral powder in the original, unopened packet until use.
Stability Limit	The oral powder mixture is stable for only 1 hour at 20 C to 30 C after mixing with food or liquid.
Child Safety	The medicine must be stored out of the sight and reach of children and pets.
Disposal	Unused or expired Reyataz must be discarded by following the official FDA recommended drug disposal guidelines.

All forms of this medicine require storage at the specified room temperatures to maintain product stability. Once the oral powder is prepared, its use is restricted to a strict one-hour time limit. The product must be stored in its original, closed container, and official labeling directs users to dispose of any unneeded or outdated product according to government-issued guidelines.